 Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50 of all patients with cancer. Management plans to expand its ongoing clinical myelopreservation trial to include two additional cohorts: an expansion cohort in small-cell lung cancer patients and a cohort in non-small-cell lung cancer patients. Company expects to present key findings of the phase 1b portion of this myelopreservation trial in the 2nd quarter of 2020. 